Science

Blog

Methane Overgrowth Study

STUDY DEEP DIVE

Could Atrantil Help Address Methane Overgrowth?

A Northwestern University clinical study explored whether Atrantil could improve symptoms, quality of life, and methane levels in patients with intestinal methanogen overgrowth (IMO), a common but under-recognized digestive condition.

Study:
Open-Label Assessment of the Efficacy of Atrantil in the Treatment of Methane-Predominate Intestinal Bacterial Overgrowth

Authors:
Darren Brenner, MD and Northwestern University Investigators

Reviewed by:
Paula Owen & Andrea Helleman

Journal:
ClinicalTrials.gov Study Registration (NCT04755673)

Scientific Oversight:
Kenneth Brown, MD

Study Type:
Independent Study

VIEW STUDY

SYNOPSIS

Evaluating a Non-Antibiotic Approach to Methane Overgrowth

Researchers at Northwestern University conducted a prospective study evaluating Atrantil in patients with intestinal methanogen overgrowth (IMO). Participants received Atrantil for 28 days and were assessed for changes in digestive symptoms, quality of life, bowel habits, and methane levels. The study was designed to explore whether a non-antibiotic approach could help address a condition for which few evidence-based treatment options currently exist.

Key Takeaways

  • Intestinal methanogen overgrowth (IMO) is associated with symptoms including bloating, distention, abdominal discomfort, and constipation.
  • Unlike traditional SIBO, methane overgrowth is linked to methanogenic archaea rather than bacterial overgrowth alone.
  • Current clinical guidelines offer limited treatment recommendations specifically for methane overgrowth.
  • Researchers designed this study to evaluate whether Atrantil could improve symptoms, quality of life, and breath methane levels in patients with IMO.
  • Participants took Atrantil for 28 days and completed symptom tracking, quality-of-life assessments, and repeat methane breath testing.
  • The study reflects growing interest in non-antibiotic approaches to managing methane-associated digestive symptoms.

WHY THIS CAUGHT OUR ATTENTION

Real-World Patients. Real-World Results.

Many digestive studies focus on highly selected patient populations. This study took a different approach.

Conducted independently through Northwestern University under the direction of Darren Brenner, MD, the study was designed to evaluate Atrantil in a real-world population experiencing methane-associated digestive symptoms. Participants were assessed across multiple symptom categories, quality-of-life measures, bowel habits, and methane levels rather than a single symptom score.

What makes this particularly interesting from a research perspective is that the study sought to evaluate whether a non-antibiotic approach could meaningfully impact a condition for which few evidence-based treatment options currently exist.

For us, the study is not simply about one product. It reflects growing interest in the relationship between methane production, microbial balance, gastrointestinal motility, and symptom development, mechanisms that sit at the center of ongoing polyphenol research.

WHAT IT MEANS FOR POLYPHENOL SCIENCE

Independent Research Into a Growing Clinical Need

Methane-associated digestive disorders remain one of the most challenging areas of gastrointestinal health. While antibiotics are often used for bacterial overgrowth, treatment options specifically targeting methane production remain limited.

This study explored whether a polyphenol-based medical food could support improvements in symptoms commonly associated with intestinal methanogen overgrowth. The findings add to a growing body of research investigating how plant-derived compounds may influence the microbial environment, fermentation patterns, and methane production within the gut.

Importantly, the value of this study extends beyond Atrantil itself. It contributes to a broader scientific conversation about whether polyphenols can play a meaningful role in supporting microbial balance and digestive health through mechanisms distinct from traditional pharmaceutical approaches.

As interest in the microbiome continues to evolve, studies like this help define where future polyphenol research may have the greatest impact.

REFERENCE

  • Brenner D. Open-Label Assessment of the Efficacy of Atrantil in the Treatment of Methane-Predominate Intestinal Bacterial Overgrowth. ClinicalTrials.gov Identifier: NCT04755673. Northwestern University. Completed 2022.
VIEW STUDY

This article is for educational purposes and summarizes published research. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Atrantil is a dietary supplement. Talk with your healthcare provider before changing any medication or supplement routine.